To attend, please ensure you are registered for the ASBMR annual meeting. 

Although regularly used in other disorders, biosimilars in osteoporosis treatment is a novel concept. The FDA recently approved the use of biosimilars as an alternative osteoporosis treatment option, potentially impacting future osteoporosis management in the USA. Join our expert faculty as they address the safety and efficacy of biosimilar alternatives for treating osteoporosis and how these therapies may be integrated into clinical practice to deliver high quality care leading to positive effects on bone health.

Presenters

Accreditation

EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

EXCEL Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Canadian CME: Through an agreement between the ACCME and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

The UEMS-EACCME®: European Union of Medical Specialists and European Accreditation Council for CME have mutual recognition agreements with the American Medical Association for live events and e-learning materials. European physicians can earn their ECMEC®s (European CME credits) by either attending a live presentation approved by an ACCME accredited provider such as EXCEL or participating in e-learning activities (on-demand webcasts) from accredited providers from the USA that have been certified for AMA PRA Category 1 Credits™.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits ^TM through their reciprocity agreements.

Educational Objectives

At the conclusion of this conference, you should be able to:

Apply strategies to facilitate early identification of patients who may be at risk for developing osteoporosis or low bone mass

Define biosimilars and how these new agents can help close the treatment gap for managing individuals with osteoporosis and those at an increased risk of fractures

Using sample patient cases, explain how biosimilars have already been incorporated as a new treatment option for patients with osteoporosis

Supporter